Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations.

Xie R, Tan LH, Polasek EC, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens DJ, Arakawa T, Knuth DW, Antal EJ.

J Clin Pharmacol. 2005 Mar;45(3):352-6. No abstract available.

PMID:
15703370
2.

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.

Dresser GK, Schwarz UI, Wilkinson GR, Kim RB.

Clin Pharmacol Ther. 2003 Jan;73(1):41-50.

PMID:
12545142
3.

The interaction between St John's wort and an oral contraceptive.

Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC.

Clin Pharmacol Ther. 2003 Dec;74(6):525-35.

PMID:
14663455
4.

Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.

Andrén L, Andreasson A, Eggertsen R.

Eur J Clin Pharmacol. 2007 Oct;63(10):913-6. Epub 2007 Aug 15.

PMID:
17701167
5.

Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.

Hafner V, Jäger M, Matthée AK, Ding R, Burhenne J, Haefeli WE, Mikus G.

Clin Pharmacol Ther. 2010 Feb;87(2):191-6. doi: 10.1038/clpt.2009.206. Epub 2009 Nov 18.

PMID:
19924124
6.

Effect of St John's wort on the pharmacokinetics of fexofenadine.

Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD.

Clin Pharmacol Ther. 2002 Jun;71(6):414-20.

PMID:
12087344
7.

Pharmacokinetic interactions of drugs with St John's wort.

Zhou S, Chan E, Pan SQ, Huang M, Lee EJ.

J Psychopharmacol. 2004 Jun;18(2):262-76. Review.

PMID:
15260917
8.

Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY.

Clin Pharmacol Ther. 2002 Sep;72(3):276-87.

PMID:
12235448
9.

Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort - and beyond!

Nowack R.

Nephrology (Carlton). 2008 Jun;13(4):337-47. doi: 10.1111/j.1440-1797.2008.00940.x. Epub 2008 Mar 17. Review.

PMID:
18363644
10.

The recovery time-course of CYP3A after induction by St John's wort administration.

Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K.

Br J Clin Pharmacol. 2008 May;65(5):701-7. doi: 10.1111/j.1365-2125.2008.03120.x. Epub 2008 Feb 20.

11.

No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.

Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H, Lehnfeld R, Frank B, Thurow K, Kundt G, Drewelow B.

Eur J Clin Pharmacol. 2009 Jan;65(1):81-7. doi: 10.1007/s00228-008-0554-y. Epub 2008 Sep 3.

PMID:
18762932
12.

Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 activity in perfused rat liver.

Dostalek M, Pistovcakova J, Jurica J, Tomandl J, Linhart I, Sulcová A, Hadasova E.

Life Sci. 2005 Dec 5;78(3):239-44. Epub 2005 Aug 25.

PMID:
16125735
13.

The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.

Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B.

Eur J Clin Pharmacol. 2006 Jan;62(1):29-36. Epub 2005 Dec 10.

PMID:
16341856
14.

The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.

Markert C, Kastner IM, Hellwig R, Kalafut P, Schweizer Y, Hoffmann MM, Burhenne J, Weiss J, Mikus G, Haefeli WE.

Basic Clin Pharmacol Toxicol. 2015 May;116(5):423-8. doi: 10.1111/bcpt.12332. Epub 2014 Nov 8.

15.

Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.

Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D.

Clin Pharmacol Ther. 2007 Oct;82(4):410-26. Epub 2007 Jun 6.

PMID:
17554244
16.

Effects of St. John's wort supplementation on ibuprofen pharmacokinetics.

Bell EC, Ravis WR, Lloyd KB, Stokes TJ.

Ann Pharmacother. 2007 Feb;41(2):229-34. Epub 2007 Feb 6.

PMID:
17284505
17.

Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.

Fuchs I, Hafner-Blumenstiel V, Markert C, Burhenne J, Weiss J, Haefeli WE, Mikus G.

Eur J Clin Pharmacol. 2013 Mar;69(3):507-13. doi: 10.1007/s00228-012-1388-1. Epub 2012 Sep 12.

PMID:
22968811
18.

In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products.

Hellum BH, Nilsen OG.

Basic Clin Pharmacol Toxicol. 2008 May;102(5):466-75. doi: 10.1111/j.1742-7843.2008.00227.x. Epub 2008 Mar 6.

19.

Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver.

Turkanovic J, Ngo SN, Milne RW.

J Pharm Pharmacol. 2009 Aug;61(8):1037-42. doi: 10.1211/jpp/61.08.0007.

PMID:
19703347
20.

Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers.

Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM.

J Clin Pharmacol. 2004 Jan;44(1):89-94.

PMID:
14681346

Supplemental Content

Support Center